Mr. Oclassen has had a historic career in drug development. He held key positions at Westwood Pharmaceuticals, Allergan, Neutrogena, Pharmaquest, NextDerm, Trancept and Oclassen Pharmaceuticals. Mr. Oclassen founded Oclassen Pharmaceuticals, Inc., a dermatologic drug development and marketing company. He served as a director from the company's inception, was President and CEO from 1985 until 1991, and became Chairman of the Board of Directors in January 1991. He served in this role until Watson Pharmaceuticals acquired the company in February 1997. He was also a founder and Chairman of the Board of NextDerm Inc., a venture that was acquired in 1999 by Procyte Corp.
In 1977, Mr. Oclassen founded the Neutrogena Dermatologics division of Neutrogena Corp. and served as President until 1982. He was employed by Allergan Pharmaceuticals from 1971 until 1977 where he was concurrently Director of Marketing for OTC ophthalmic products, and General Manager of the Dermatology Division. Mr. Oclassen previously held marketing and sales positions with Westwood Pharmaceuticals, which was founded by his father Charles A. Oclassen, and with Wm. H. Rorer Pharmaceuticals. He received a B.S. in zoology from San Diego State University in 1965. Mr. Oclassen is a member of the Cutaneous Therapy Society and the North American Clinical Dermatology Society. He was previously elected as the first non-physician member of the Executive Committee of the Dermatology Foundation.
Dennis Brown, PhD
Dr. Brown has over 20 years of drug discovery and development experience. He is the cofounder of ChemGenex Pharmaceuticals Inc, Matrix Pharmaceuticals Inc, Valent Technologies Inc. and Del Mar Pharmaceuticals Inc. His experience ranges from compound synthesis and screening through the registration of directed clinical trials. During his career he has held many different executive roles and has managed technology development as well as both private and public financings. He received his B.A. in Biology and Chemistry (1971), M.S. in Cell Biology (1975) and Ph.D. in Radiation and Cancer Biology (1979), all from New York University. Dr. Brown also served as an assistant professor of radiology at Harvard Medical School. Dr. Brown had 34 issued US patents and applications, many with foreign counterparts.
Mark de Souza, PhD
Dr. de Souza is a biotech entrepreneur in the rare disease and dermatology spaces with more than 20 years of experience creating value for investors. He is the former founder and CEO of Lotus Tissue Repair (acquired by Shire) and is currently the executive chairman of Pellepharm and president of Chromaderm Inc. He served as Vice President of Business Development at Dyax Corp, a biopharmaceutical company which discovered, developed and commercialized Kalbitor. Dr. de Souza completed his PhD and Post Doc at the University of California, Berkeley.